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Dr Michael P. Fischbein (Stanford, Calif). Excellent presenta-
tion. For my first question, did you look for autophagy directly in
your heart specimens rather than just indirectly by measuring the
upstream and downstream markers that you showed today?
Dr Sabe. Although we did look at specific essential markers of
autophagy, immunoblotting in and of itself is an indirect measure,
as you alluded. If we wanted to study this directly, we have to use
electron microscopy. That is actually the reference standard for
studying autophagy. How that is done is one looks for the
autophagosome vacuole in formation at different stages using
electron microscopy, and, as one can imagine, that requires quite
a bit of experience and expertise. One of the greatest criticisms
of this technique is that because autophagy is a ubiquitous
process (ie, it occurs in cells all the time), using electron
microscopy to study it is not objectively quantifiable, and the
specificity might not be ideal. Thus, our method we thought was
reproducible, something we could objectively quantify, and was
specific.
Dr Fischbein. The second question is biologic proof of
concept that autophagy is actually playing a role in your ischemic
myocardium. Did you consider blocking autophagy?
Dr Sabe. Because it is an essential process, you cannot
completely block it in a large animal model such as this. That
being said, other groups have had knockout mice with essential
markers ‘‘blocked out.’’ Some of the criticism of this has been
that with the knockout mice, compensatory mechanisms have
occurred that might have confounded the results.
Another technique is actually just diminishing autophagy with
medications, such as chloroquine, and that is certainly something
that has been done in mouse models and something that we could
definitely try. Also, just to clarify, when they did do that in
the study in which they used chloroquine, the infarct size
was increased and the ventricular remodeling after infarct was
worse.798 The Journal of Thoracic and Cardiovascular SurgDr Fischbein. Also, if autophagy is as protective as you are
suggesting, did you see an actual decrease in cardiomyocyte
apoptosis or necrosis with your treatment?
Dr Sabe.That is a good question. I think the key to that question
is ‘‘whether autophagy is good?’’ and ‘‘how to prove it by studying
apoptosis and necrosis.’’ We began studying apoptosis, and we do
have some preliminary data. As I mentioned, the key question is
where apoptosis might overlap with autophagy signaling. Some
of that data will be coming, and I think it will be interesting.
As far as studying necrosis, we have not done that. That can be
done, obviously, with tissue staining. Again, how well or easy
that is to quantify would be questionable. However, using
magnetic resonance imaging in this animal model and even
clinically looking at scar tissue would also be interesting and
another future direction to move toward.
Dr Fischbein. Last question is, in all our research, we are
always looking for translational potential, and so, how would
you predict that we are going to use this drug clinically?
Dr Sabe. That is a great question. At this point, I think more
preclinical studies are needed. That is part of the reason we did
this in a clinically relevant large animal model, which we think
more readily translates to our patient population. That said,
resveratrol is available over the counter as an herbal supplement
and has been for a long time. Also, resveratrol analogs have
been, and are currently being, used safely in clinical trials
investigating the potential benefits against cancer and dementia.
I would design a study giving resveratrol for perhaps several
weeks before coronary artery bypass grafting in diabetic patients.
It would be interesting to study the difference between patients
with poorly controlled diabetes and those with well-controlled
diabetes. I think you could also do that in a broader scope in a
clinical trial, just giving it to patients with angina and diabetes.
Somebody had alluded to this earlier, but at this point I do not
see resveratrol being used in its current form. You might need a
stronger analog or a more potent analog. That might be because
resveratrol is more likely a disease-modifying drug that reduces
the risk factors. Also, a number of these patients have already
been identified and are receiving insulin and are taking metformin
and statins. They might already be receiving the benefits of
resveratrol. I think in the future we are going to be using more
potent analogs once we have a better understanding of how this
works.
Dr Fischbein. Thank you. Nice presentation.
Dr Frank A. Baciewicz, Jr (Detroit, Mich). Are there clinical
trials already studying autophagy in the short term just for
coronary cases and other cardiac surgery cases? Are you aware
of any studies?
Dr Sabe. Just studying autophagy in and of itself, yes. Actually,
they were studying autophagy during bypass surgery before and
after cardioplegia using atrial tissue sampling. They only
considered autophagy in these studies, not with resveratrol, but
just specifically studying autophagy and its upregulation in
different patients during surgery, before and after cardioplegia.
That was recently published.
Dr Baciewicz. What medications are they using?
Dr Sabe. I am not sure whether these patients were getting
any additional medications—I do not think they were receiving
anything. I think they were specifically just studying atrialery c February 2014
Sabe et al Evolving Technology/Basic Sciencesampling and measuring autophagy as more of what is occurring
during bypass before and after cardioplegia/cardiopulmonary
bypass and whether autophagy is a critical process and how
autophagy is affected and how that is related to patient outcomes.
Dr Baciewicz. I thought they gave drugs to try to alter the
autophagy rate, and they showed some difference.
Dr Sabe. I am thinking of the report by Dr Mentzer. I do not
think they did, but I am not sure. Is that what you are referring to?
Dr Baciewicz. Yes.
Dr Sabe. I do not believe they did that, but I would have to
review it again. I do not think they did. I do not think they gave
any medication. I think they were just studying autophagy and
whether it is induced after surgery as more just to determine
what happens, and whether it is good or bad.The Journal of Thoracic and CaDr Y. Joseph Woo (Philadelphia, Pa). Did you prove
hypocholesteremia in the latter 2 groups?
Dr Sabe. Yes, we did. That was actually in a previous publica-
tion, and we did measure the triglyceride and cholesterol levels.
Dr Woo. Did you also measure the caloric intake?
Dr Sabe. These pigs were given either their regular chow or a
fatty diet. The fatty diet was not really a burger and fries, such
as on my slides—it was a fat supplemented diet. Also, the pigs
would eat everything—that was observed to be sure. The diet
was regimented with exactly 2248 kcal for the high cholesterol
group.
DrWoo. Thus, the ingestion of resveratrol did not increase their
appetite or their caloric intake?
Dr Sabe. No. They were given a fixed diet.rdiovascular Surgery c Volume 147, Number 2 799
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